Cyteir Therapeutics Inc. (CYT)
NASDAQ: CYT
· Real-Time Price · USD
3.02
-0.07 (-2.27%)
At close: Mar 15, 2024, 9:00 PM
Cyteir Therapeutics Revenue Breakdown
| Period Ending | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | Dec 31, 2012 | Sep 30, 2012 | Jun 30, 2012 | Mar 31, 2012 | Dec 31, 2011 | Jun 30, 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aerospace Materials Revenue | 261.5M | 70.2M | 69.7M | 63.3M | 67.5M | 74.3M | 66.2M | 68.4M | 65.9M | 100K | 200K | 200K | 200K | 300K | 200K | 100K | 72.9M |
| Aerospace Materials Revenue Growth | +272.51% | +0.72% | +10.11% | -6.22% | -9.15% | +12.24% | -3.22% | +3.79% | +65800.00% | -50.00% | 0.00% | 0.00% | -33.33% | +50.00% | +100.00% | -99.86% | n/a |
| Additive Technologies Revenue | 65.7M | 264.8M | 259.3M | 244.7M | 250.8M | 262.4M | 243.4M | 240.6M | 235.9M | 200K | 100K | 94.3M | 98.1M | 100.2M | 91.6M | 89.5M | 81.9M |
| Additive Technologies Revenue Growth | -75.19% | +2.12% | +5.97% | -2.43% | -4.42% | +7.81% | +1.16% | +1.99% | +117850.00% | +100.00% | -99.89% | -3.87% | -2.10% | +9.39% | +2.35% | +9.28% | n/a |
| In Process Separation Revenue | 106.3M | 109.6M | 107.3M | 102.2M | 108.2M | 103.9M | 96.2M | 96.3M | 91.2M | 106.4M | 88.8M | n/a | n/a | n/a | n/a | n/a | n/a |
| In Process Separation Revenue Growth | -3.01% | +2.14% | +4.99% | -5.55% | +4.14% | +8.00% | -0.10% | +5.59% | -14.29% | +19.82% | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Industrial Materials Revenue | 63.8M | 63.6M | 78.7M | 75.8M | 80.3M | 86.5M | 83.2M | 76.4M | 70.9M | 85M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Industrial Materials Revenue Growth | +0.31% | -19.19% | +3.83% | -5.60% | -7.17% | +3.97% | +8.90% | +7.76% | -16.59% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 |
|---|---|---|---|---|
| Asia Pacific Revenue | 236.7M | 216.6M | 188.5M | 104.6M |
| Asia Pacific Revenue Growth | +9.28% | +14.91% | +80.21% | n/a |
| Emea Revenue | 631M | n/a | n/a | n/a |
| Emea Revenue Growth | n/a | n/a | n/a | n/a |
| Other Americas Revenue | 227.2M | n/a | n/a | n/a |
| Other Americas Revenue Growth | n/a | n/a | n/a | n/a |
| United States Revenue | 912.8M | n/a | n/a | n/a |
| United States Revenue Growth | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 2.5M | 4.2M | 4.11M | 2.58M | 3.49M | 3.43M | 4.04M | 3.61M | 3.55M | 2.42M | 1.72M | 1.46M | 831K | 875K | 1.01M |
| Selling, General, and Administrative Revenue Growth | -40.65% | +2.29% | +59.12% | -25.92% | +1.57% | -15.09% | +12.09% | +1.69% | +46.45% | +40.49% | +17.84% | +76.05% | -5.03% | -13.28% | n/a |
| Research and Development Revenue | 2.68M | 5.4M | 9.31M | 7.47M | 8.27M | 8.79M | 10.09M | 8.26M | 8.21M | 8.89M | 5.61M | 3.92M | 4.21M | 3.63M | 5M |
| Research and Development Revenue Growth | -50.47% | -41.98% | +24.66% | -9.70% | -5.94% | -12.83% | +22.20% | +0.61% | -7.66% | +58.31% | +43.30% | -7.05% | +15.99% | -27.35% | n/a |